Compare FATE & RANI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FATE | RANI |
|---|---|---|
| Founded | 2007 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 125.6M | 106.9M |
| IPO Year | 2013 | 2021 |
| Metric | FATE | RANI |
|---|---|---|
| Price | $2.11 | $0.79 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 11 | 5 |
| Target Price | $5.74 | ★ $7.20 |
| AVG Volume (30 Days) | ★ 1.6M | 503.4K |
| Earning Date | 11-12-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 29.88 | ★ 57.14 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $6,646,000.00 | $1,633,000.00 |
| Revenue This Year | N/A | $283.19 |
| Revenue Next Year | N/A | $5.99 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 58.85 |
| 52 Week Low | $0.95 | $0.45 |
| 52 Week High | $3.23 | $3.87 |
| Indicator | FATE | RANI |
|---|---|---|
| Relative Strength Index (RSI) | 34.55 | 47.82 |
| Support Level | $1.81 | $0.73 |
| Resistance Level | $2.62 | $0.84 |
| Average True Range (ATR) | 0.15 | 0.05 |
| MACD | -0.03 | 0.00 |
| Stochastic Oscillator | 12.50 | 46.26 |
Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. The company is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.
Rani Therapeutics Holdings Inc is a clinical-stage biotherapeutics company advancing technologies to enable the development of orally administered biologics to provide patients, physicians, and healthcare systems with a convenient alternative to painful injections. The company has developed the RaniPill capsule, which is designed to deliver a wide variety of drug substances, including antibodies, proteins, peptides, and oligonucleotides. RaniPill is a proprietary and patented platform technology, intended to replace subcutaneous or IV injection of biologics with oral dosing. The company is also engaged in developing RaniPill HC, which is intended to enable the delivery of drug payloads in liquid form with high bioavailability.